Pages that link to "Q28301311"

The following pages link to Fatty acid oxidation abnormalities in childhood-onset spinal muscular atrophy: primary or secondary defect(s)? (Q28301311):

Displaying 33 items.

• Is spinal muscular atrophy a disease of the motor neurons only: pathogenesis and therapeutic implications? (Q26774987) (← links)
• Abnormal fatty acid metabolism in childhood spinal muscular atrophy (Q28138438) (← links)
• Phase II open label study of valproic acid in spinal muscular atrophy (Q28475498) (← links)
• Consensus Statement for Standard of Care in Spinal Muscular Atrophy (Q29028573) (← links)
• Immune dysregulation may contribute to disease pathogenesis in spinal muscular atrophy mice (Q33614675) (← links)
• ROCK inhibition as a therapy for spinal muscular atrophy: understanding the repercussions on multiple cellular targets (Q34103656) (← links)
• Vitamin D intake is inadequate in spinal muscular atrophy type I cohort: correlations with bone health (Q34653462) (← links)
• Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings (Q35101826) (← links)
• Glucose metabolism and pancreatic defects in spinal muscular atrophy (Q35101838) (← links)
• The floppy infant: contribution of genetic and metabolic disorders (Q35226294) (← links)
• Observational study of caloric and nutrient intake, bone density, and body composition in infants and children with spinal muscular atrophy type I. (Q36357056) (← links)
• A plural role for lipids in motor neuron diseases: energy, signaling and structure (Q37594297) (← links)
• Anesthesia and spinal muscle atrophy. (Q38100295) (← links)
• Spinal muscular atrophy: new findings for an old pathology. (Q38113286) (← links)
• Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? (Q38123249) (← links)
• Proximal spinal muscular atrophy: current orthopedic perspective (Q38176600) (← links)
• Motor neuron mitochondrial dysfunction in spinal muscular atrophy (Q39733042) (← links)
• Defects in pancreatic development and glucose metabolism in SMN-depleted mice independent of canonical spinal muscular atrophy neuromuscular pathology. (Q40435457) (← links)
• Responses to Fasting and Glucose Loading in a Cohort of Well Children with Spinal Muscular Atrophy Type II. (Q40445328) (← links)
• 90th ENMC international workshop: European Spinal Muscular Atrophy Randomised Trial (EuroSMART) 9-10 February 2001, Naarden, The Netherlands (Q43659789) (← links)
• Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape. (Q47700306) (← links)
• Stress-Induced Ketoacidosis in Spinal Muscular Atrophy: An Under-Recognized Complication. (Q53733437) (← links)
• High resolution respirometry of permeabilized skeletal muscle fibers in the diagnosis of neuromuscular disorders (Q53964474) (← links)
• Alternative mRNA Splicing in the Pathogenesis of Obesity. (Q54971907) (← links)
• Interventions Targeting Glucocorticoid-Krüppel-like Factor 15-Branched-Chain Amino Acid Signaling Improve Disease Phenotypes in Spinal Muscular Atrophy Mice. (Q55369340) (← links)
• Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice (Q57463072) (← links)
• Lipid Myopathies (Q60949509) (← links)
• Efficacy and Safety of Valproic Acid for Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis (Q63090193) (← links)
• Euglycemic Ketoacidosis in Spinal Muscular Atrophy (Q64234845) (← links)
• Severe ketoacidosis in a patient with spinal muscular atrophy (Q89440689) (← links)
• Phosphatase and tensin homologue: a therapeutic target for SMA (Q89700534) (← links)
• Low fat diets increase survival of a mouse model of spinal muscular atrophy (Q90684354) (← links)
• Abnormal fatty acid metabolism is a core component of spinal muscular atrophy (Q92554706) (← links)